Escitalopram for Head and Neck Cancer Patients Cut Depression in Half

Prophylactic use of the SSRI escitalopram decreased the occurrence of depression in patients with head and neck cancers by 50% and resulted in significantly improved quality of life for 3 months after drug cessation, according to the results of the PROTECT trial.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news